Sickle Cell (Splenic Sequestration)MANAGEMENT

HEMATOLOGIC AND ONCOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

713 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Acute chest syndrome Acute Hemolytic Transfusion Reaction Anticoagulant reversal (warfarin, DOAC, heparin)Aplastic Anemia (Crisis)Autoimmune Hemolytic Anemia CAR-T and cytokine release syndrome Coagulopathy Delayed Hemolytic Transfusion Reaction Disseminated Intravascular Coagulation (DIC)Essential Thrombocythemia Febrile Non-hemolytic Transfusion Reaction Graft Versus Host Disease (Acute)Hemolytic Uremic Syndrome (HUS)Hemophilia A (Bleeding Crisis)Heparin-Induced Thrombocytopenia (HIT)Hyperviscosity syndrome Immune checkpoint inhibitor toxicity Immune Thrombocytopenic Purpura (ITP)Leukemoid Reaction Leukostasis Massive transfusion protocol Myelofibrosis Neutropenic enterocolitis (typhlitis)Paroxysmal Nocturnal Hemoglobinuria Polycythemia Vera (Crisis)Pure Red Cell Aplasia Sickle Cell (Acute Chest Syndrome)Sickle Cell (Splenic Sequestration)Sickle cell crisis (vaso-occlusive)Symptomatic anemia Thrombocytopenia (severe)Thrombotic Thrombocytopenic Purpura (TTP)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Tumor lysis syndrome Von Willebrand Disease (Bleeding)

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp54

Immediate resuscitation priorities

›ABCs and vascular access

›Two large-bore IV access immediately

›Intraosseous access if IV not feasible

›Central access if hemodynamic collapse

›Supplemental oxygen for SpO2 < 95%

›Target SpO2 >= 95% in SCD

›High-flow O2 via non-rebreather if severe

›Cardiac monitor and continuous pulse oximetry

›12-lead ECG if tachycardia or arrhythmia

›Serial abdominal exam documentation

›Volume resuscitation for hypovolemic shock

›Isotonic crystalloid bolus 20 mL/kg IV for hemodynamic instability

›Repeat as needed pending blood availability

›Avoid excessive crystalloid once blood products available

›Type and crossmatch immediately

›Request extended antigen-matched sickle-negative blood

›Contact blood bank early for phenotype-matched units

›Emergency transfusion trigger

›Hemoglobin < 5 g/dL or hemodynamic instability

›Simple RBC transfusion 3 to 5 mL/kg aliquots

›Check hemoglobin after each aliquot before next

›Target hemoglobin 8 g/dL maximum per NHLBI

›AAP recommends not exceeding 10 g/dL

›Sequestered RBCs re-enter circulation as crisis resolves

Monitoring and escalation

›Monitoring bundle

›Serial hemoglobin and hematocrit every 2 to 4 hours

02History/hx66

Presentation features

›Core symptoms

›Abrupt onset abdominal fullness or LUQ pain

›Progression over hours

›Generalized abdominal distension

›Sudden pallor noted by caregiver

›Listlessness

›Irritability especially in infants

›Associated systemic symptoms

›Nausea and vomiting

›Lethargy and weakness

›Breathlessness and rapid heart rate

›Temporal context

›Preceding febrile illness or viral infection common trigger

›Recent upper respiratory illness

›Recent gastrointestinal illness

›Abrupt onset distinguishes ASSC from chronic hypersplenism

›Hours not days for acute crisis

›Caregiver perceived sudden change

Baseline and prior history

›SCD-specific baseline information

›Steady-state hemoglobin level

›Essential comparator for defining drop of >= 2 g/dL

›Typically 6 to 9 g/dL in HbSS

›Known spleen size baseline

›Prior measurements if available

›Caregiver trained palpation findings

›Prior ASSC episodes

03Physical Exam/exam60

Vitals and general appearance

›Vital sign pattern in ASSC

›Tachycardia

›Often earliest sign of crisis

›Proportional to degree of hypovolemia

›Hypotension

›Indicates cardiovascular compromise

›SBP < 90 mmHg or MAP < 65 mmHg

›Tachypnea

›Compensatory in anemia

›Respiratory rate >= 30 per minute as severity marker

›Fever

›Raises concern for concurrent sepsis

›Functional asplenia increases infection risk

›General appearance

›Pallor

›Conjunctival pallor

›Palmar and nail bed pallor

›Level of consciousness

›Altered sensorium suggests severe hypovolemia

›CNS event consideration with neurologic changes

›Diaphoresis

›Shock physiology marker

›Peripheral perfusion assessment

Abdominal exam

›Splenic assessment

›Palpable spleen below costal margin

›May cross midline in severe sequestration

04Differential Diagnosis/ddx44

Life-threatening conditions

›Immediate threats to exclude

›Sepsis or bacteremia

›ICD-10 A41.9

›Functional asplenia markedly increases risk

›Encapsulated organism risk especially Streptococcus pneumoniae

›Hypovolemic shock from other cause

›Internal hemorrhage consideration

›Rapid clinical assessment

›Concurrent acute chest syndrome

›ICD-10 J98.09

›May coexist with ASSC

›Pulmonary infiltrate plus fever plus respiratory symptoms

Hematologic differentials

›Anemia with reticulocytopenia

›Aplastic crisis from parvovirus B19

›ICD-10 D57.02

›Reticulocyte count suppressed not elevated

›No splenomegaly

›Delayed hemolytic transfusion reaction

›Within 28 days of prior transfusion

›Falling hemoglobin with hyperbilirubinemia

›Antibody screen positive

›Other sequestration variants

›Hepatic sequestration

›ICD-10 D57.00

›Right-sided enlargement not left

›Elevated liver function tests

05Laboratory Tests/lt56

Urgent hematology labs

›Complete blood count with differential

›Hemoglobin drop >= 2 g/dL below baseline diagnostic criterion

›Baseline 6 to 9 g/dL in HbSS

›Baseline higher in HbSC approximately 10 to 12 g/dL

›Reticulocyte count

›Elevated up to 25% above baseline in ASSC

›Distinguishes from aplastic crisis where reticulocytes are suppressed

›Platelet count

›Mild to moderate thrombocytopenia typical

›Less than 150 x 10^9/L common

›White blood cell count

›Leukocytosis common in SCD at baseline

›Significant elevation raises sepsis concern

›Blood smear review

›Sickle cells and target cells

›Polychromasia indicating reticulocytosis

›Nucleated RBCs in severe crisis

Transfusion and crossmatch

›Pre-transfusion testing

›Type and crossmatch

›Extended red cell antigen phenotype if available

›Request sickle-negative units

›Direct antiglobulin test

›If delayed hemolytic transfusion reaction possible

›Prior alloantibody panel review

›Alloantibody identification

›Critical to prevent hemolytic reactions

06Diagnostic Tests/dt78

Scoring Systems

›Severity classification for ASSC

›Mild ASSC

›Hemoglobin drop >= 2 g/dL below baseline

›Hemodynamically stable

›Spleen palpable but not massive

›Moderate ASSC

›Hemoglobin 4 to 6 g/dL

›Tachycardia without hypotension

›Spleen significantly enlarged

›Severe ASSC

›Hemoglobin < 4 g/dL

›Hemodynamic instability or shock

›Altered mental status

›ASSC diagnostic triad

›Criterion 1: Acute splenomegaly

›New or increasing palpable spleen

›Comparison to documented baseline critical

›Criterion 2: Hemoglobin drop >= 2 g/dL below patient baseline

›Clinical diagnosis based on this threshold

›Not absolute hemoglobin level

›Criterion 3: Reticulocytosis

›Preserved erythropoiesis distinguishes from aplastic crisis

›Count elevated above patient baseline

›Pediatrics clinical prediction

›No validated risk score specific to ASSC

›Clinical assessment remains primary

›Severity based on hemodynamics and hemoglobin nadir

07Disposition/dispo45

Admission criteria

›All ASSC patients require hospitalization

›This is a medical emergency without exception

›Rapid re-sequestration risk if discharged acutely

›Rebound hyperviscosity risk as sequestered cells release

›Documentation of hematology consultation

›Mandatory for all admissions

›Discussion of transfusion plan and splenectomy timing

›ICU admission indications

›Hemoglobin < 5 g/dL with hemodynamic instability

›Vasopressor requirement

›Need for aggressive resuscitation

›Altered mental status

›Severe hypovolemia effect

›Concurrent CNS event exclusion

›Failure to stabilize with initial transfusion

›Ongoing sequestration

›Escalating transfusion requirement

Level of care by severity

›Monitored bed for stable patients

›Serial hemoglobin every 2 to 4 hours

›Serial abdominal exams

›Continuous cardiorespiratory monitoring

›Stable hemodynamics and improving hemoglobin

›Responding to initial transfusion

›No ongoing sequestration signs

›Transfer criteria

›Facility without pediatric hematology capability

08Treatment/t77

Immediate stabilization

›Resuscitation sequence

›Supplemental oxygen

›Titrate to SpO2 >= 95%

›High-flow non-rebreather for significant hypoxemia

›IV crystalloid bolus for hemodynamic instability

›Normal saline or lactated Ringer 20 mL/kg

›Repeat as needed pending blood availability

›Emergent type and crossmatch

›O-negative uncrossmatched blood if critically unstable

›Extended antigen-matched blood as soon as available

Transfusion therapy

›Simple RBC transfusion protocol

›Aliquot-based administration

›3 to 5 mL/kg per aliquot

›Check hemoglobin after each aliquot

›Hemoglobin target ceiling

›Do not exceed 8 g/dL per NHLBI Expert Panel 2014

›AAP recommends ceiling of 10 g/dL

›Sequestered RBCs auto-transfuse back into circulation as crisis resolves

›Blood product specifications

›Extended antigen-matched units where possible

›Sickle-negative donor blood

›Leukoreduced packed RBCs

›Overtransfusion prevention

›Hyperviscosity syndrome risk

›Sequestered RBCs re-enter circulation during resolution

›Risk of stroke or cardiac events if hemoglobin too high

›Exchange transfusion not routinely indicated for isolated ASSC

›Consider only with concurrent acute chest syndrome or stroke

›Specialist guidance required

Infection management

›Empiric antibiotics for febrile ASSC

›Ceftriaxone IV for encapsulated organism coverage

›50 to 100 mg/kg IV daily (maximum 2 g)

›Blood cultures before administration if feasible

›Caution with ceftriaxone

›Drug-induced hemolysis risk in SCD patients

›Observe for acute hemolytic reaction post-infusion

›Broader coverage if septic shock

›Add vancomycin for MRSA coverage

›Piperacillin-tazobactam for gram-negative sepsis

Pain management

›Analgesia approach

›Opioid analgesia for moderate to severe pain

›Morphine 0.1 mg/kg IV every 3 to 4 hours

›Titrate to pain relief

›NSAID caution

›Avoid if thrombocytopenic

›Renal function consideration

›Non-opioid adjuncts

›Acetaminophen 15 mg/kg IV or PO every 6 hours

›Maximum dose 75 mg/kg per day

Recurrence prevention

›Splenectomy for recurrence prevention

›Recommended after recurrent ASSC or single life-threatening episode

›Class I recommendation NHLBI 2014

›Preferred timing age greater than 2 to 3 years to reduce post-splenectomy sepsis risk

›Pre-operative vaccinations

›Pneumococcal PCV and PPSV23

›Meningococcal vaccines

›Haemophilus influenzae type b

›Administer at least 2 weeks before splenectomy

›Post-splenectomy prophylactic penicillin

›Penicillin VK 125 mg PO twice daily age under 3 years

›250 mg PO twice daily age 3 and above

›Lifelong in patients with asplenia and SCD

›Chronic transfusion as bridge therapy

›Bridge to splenectomy in very young children under 2 years

›Monthly transfusions to maintain HbS less than 30%

›Evidence of benefit is limited per Cochrane 2017

›Iron overload monitoring required

›Ferritin and liver iron monitoring

›Chelation therapy planning

›Hydroxyurea for long-term disease modification

›Not treatment for acute crisis

›Reduces HbS polymerization by increasing HbF

›May alter natural history of splenic complications

›Standard dosing

›Starting dose 15 to 20 mg/kg per day orally

›Titrate by 5 mg/kg per day every 8 weeks

›Maximum 35 mg/kg per day

09Special Populations/sp66

Pregnancy

›ASSC in pregnancy

›Rare but reported in HbSC and HbSS

›SCD affects approximately 0.1% of pregnancies in high-prevalence populations

›Spleen may not have fully autoinfarted in HbSC

›Imaging considerations

›Ultrasound preferred over CT due to radiation

›MRI without gadolinium acceptable if needed

›Transfusion in pregnancy

›Maternal hemoglobin target consideration

›Fetal monitoring during resuscitation if viable gestation

›Obstetric and hematology co-management

›Early obstetric consultation

›Fetal well-being assessment

›Antibiotic safety in pregnancy

›Ceftriaxone acceptable in all trimesters

›Category B safety profile

›Avoid prolonged use near term due to biliary sludge risk

›Avoid fluoroquinolones

›Cartilage toxicity concern

›Alternative coverage if needed

Geriatric

›ASSC in older adults

›Primarily affects HbSC and HbSbeta+-thalassemia genotypes in adults

›HbSS typically autoinfarcts spleen by childhood

›HbSC retains splenic function longer

›Atypical presentation

›May lack fever response

10Background/b74

Epidemiology

›Incidence and prevalence

›Second most common cause of death in first decade of life in SCD

›Accounts for 15 to 44% of deaths in this age range

›Most common cause of acute anemia in children with SCD

›Lifetime prevalence in children with SCD

›7 to 30% depending on genotype

›Higher in HbSS and HbSbeta0-thalassemia

›Recurrence rate

›Approximately 50 to 78% after first episode

›Diminishing intervals between crises

›Genotype risk distribution

›Risk hierarchy by genotype

›HbSbeta0 > HbSS > HbSC in cumulative prevalence

›HbSC retains splenic function into adolescence and adulthood

›Adults with HbSC can develop ASSC beyond childhood

›Geographic distribution

›Highest burden in sub-Saharan Africa

›Significant prevalence in Caribbean, South America, Mediterranean, Middle East

›SCD affects approximately 300,000 births per year globally

Pathophysiology

›Acute sequestration mechanism

›Sickled RBC trapping in splenic sinusoids

›Effective intravascular hypovolemia despite preserved total body RBC mass

›Large volumes of blood pooled in spleen

›Splenic enlargement

›Rapid increase in splenic volume

›Capsule stretch causes LUQ pain

›Spleen may hold up to 40% of circulating RBC volume

›Trigger mechanisms

›Viral or bacterial infection increases sickling

›Hypoxia and dehydration exacerbate sickling

›Splenic venous congestion from sickled cells

›Resolution physiology

›Sequestered RBCs re-enter circulation during recovery

›Hemoglobin may rise above pre-transfusion level

›Risk of hyperviscosity if over-transfused

›Autoinfarction

›Progressive loss of splenic function from repeated sickling

›Functional asplenia by age 5 in most HbSS patients

›HbSC may retain splenic function much longer

›Complication pathways

›Cardiovascular collapse

›Death within hours without intervention

›Effective hypovolemia from splenic pooling

›Hyperviscosity syndrome

›Post-transfusion when sequestered cells release

›Stroke and thrombosis risk

Therapeutic Considerations

›Transfusion strategy principles

›Aliquot-based approach prevents overtransfusion

›Hemoglobin ceiling prevents hyperviscosity

›Sequestered cells will auto-transfuse during recovery

›Extended antigen matching reduces alloimmunization

›At minimum C, E, and K antigen matching

›Alloimmunization complicates future transfusions

›Exchange transfusion role

›Not routine for isolated ASSC

›Reserve for concurrent acute chest syndrome or stroke

›Recurrence prevention strategy

›Splenectomy after first severe or recurrent episode

›Curative for ASSC prevention

›Deferred until age 2 to 3 years minimum

›Post-splenectomy sepsis risk with encapsulated organisms

›Hydroxyurea modifies natural history

›Increases fetal hemoglobin reducing sickling

›Does not directly prevent ASSC but reduces overall SCD morbidity

›Penicillin prophylaxis mandatory in asplenia

›Continued lifelong after splenectomy in SCD

›Amoxicillin alternative for penicillin-tolerant patients

›Parental education as treatment

›Daily splenic palpation

›Enables early recognition of crisis

›Reduces time to emergency presentation

›Emergency action plan

›Pre-established contact with emergency department

›Home oximeter for some high-risk families

11Patient Discharge Instructions/pdi57

copy discharge instructions

›Understanding your diagnosis

›Your child has sickle cell disease with a condition called acute splenic sequestration crisis

›The spleen temporarily trapped blood cells causing severe anemia

›This is a medical emergency that required transfusion

›This condition can recur

›Recurrence rate is approximately 50%

›Your hematology team will discuss prevention options including surgery

›Daily monitoring at home

›Daily splenic palpation as taught by your care team

›Check for spleen enlargement every morning

›Compare to known baseline size

›Watch for pallor

›Check inner eyelids, palms, and nail beds

›Call for emergency care if sudden pallor appears

›Track activity level and energy

›Significant fatigue or lethargy is a warning sign

›Inability to feed or play as normal in infants

›Medications

›Continue all prescribed medications as directed

›Penicillin prophylaxis twice daily is essential

›Hydroxyurea if prescribed

›Vaccinations

›Ensure all scheduled vaccines are up to date

›Pneumonia and meningitis vaccines especially important

›Hydration and activity

›Adequate fluid intake daily

›Dehydration can worsen sickle cell disease

12References/r36

Guidelines and key sources

›Primary guidelines

›NHLBI Expert Panel Report 2014: Evidence-Based Management of Sickle Cell Disease

›National Heart Lung and Blood Institute

›Transfusion targets and recurrence prevention recommendations

›American Academy of Pediatrics: Health Supervision for Children and Adolescents With Sickle Cell Disease 2024

›Yates AM, Aygun B, Nuss R, Rogers ZR

›Daily palpation, transfusion protocol, family education

›GeneReviews Sickle Cell Disease 2025

›Bender MA, Carlberg K

›Comprehensive disease management including ASSC

Key literature

›Landmark studies and reviews

›Kavanagh PL, Fasipe TA, Wun T. Sickle Cell Disease: A Review. JAMA 2022

›Comprehensive review of SCD management

›Diagnostic criteria and treatment principles for ASSC

›Owusu-Ofori S, Remmington T. Splenectomy Versus Conservative Management for Acute Sequestration Crises. Cochrane Database of Systematic Reviews 2017

›Evidence comparing splenectomy to conservative management

›Limited evidence base highlights need for individualized decision-making

›George A, Conneely SE, Mangum R, et al. Splenic complications in pediatric sickle cell disease. Pediatric Blood and Cancer 2024

›Retrospective cohort review of genotype-specific risk

›Prevalence data and cumulative risk by genotype

›Stuart MJ, Nagel RL. Sickle-Cell Disease. Lancet 2004

›Pathophysiology and natural history overview

›HbF protective role described

›Rees DC, Williams TN, Gladwin MT. Sickle-Cell Disease. Lancet 2010

›Treatment principles including transfusion guidance

›Extended antigen matching recommendations

Learn More: Sickle Cell (Splenic Sequestration)→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.